LON:HIK - Hikma Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: GBX 2,717.50
Forecasted Upside: 10.11 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
0 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

GBX 2,468 As of 06/14/2021 11:31 AM ET

▲ +21 (0.86%)

1 month | 3 months | 12 months

Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

GBX 2,717.50

▲ +10.11% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,717.50, with a high forecast of GBX 2,860 and a low forecast of GBX 2,600. The average price target represents a 10.11% upside from the last price of GBX 2,468.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Hikma Pharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/22/2019

0 strong buy ratings
6 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/21/2020

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

6/19/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

9/17/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

12/16/2020

0 strong buy ratings
6 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

3/16/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/15/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/14/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Details
6/8/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Reiterated Rating	Buy	GBX 2,610	i
5/6/2021	Barclays	Reiterated Rating	Overweight	GBX 2,800	i
2/1/2021	Citigroup	Reiterated Rating	Buy		i
9/2/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Reiterated Rating	Buy		i
9/2/2020	Citigroup	Reiterated Rating	Buy		i
7/30/2020	Peel Hunt	Boost Price Target	Buy	GBX 2,380 ➝ GBX 2,860	i
7/7/2020	Morgan Stanley	Upgrade	Overweight	GBX 2,200 ➝ GBX 2,600	i
7/2/2020	Peel Hunt	Reiterated Rating	Buy		i
6/23/2020	Peel Hunt	Reiterated Rating	Buy		i
6/3/2020	Peel Hunt	Reiterated Rating	Buy		i
5/22/2020	Peel Hunt	Reiterated Rating	Buy		i
4/30/2020	Peel Hunt	Reiterated Rating	Buy		i
4/28/2020	Barclays	Boost Price Target	Equal Weight	GBX 1,950 ➝ GBX 2,200	i
4/24/2020	The Goldman Sachs Group	Downgrade	Neutral	GBX 2,200 ➝ GBX 2,400	i
4/24/2020	Peel Hunt	Reiterated Rating	Buy		i
4/3/2020	Citigroup	Boost Price Target	Buy	GBX 2,150 ➝ GBX 2,500	i
4/2/2020	JPMorgan Chase & Co.	Upgrade	Overweight	GBX 1,850 ➝ GBX 2,400	i
4/2/2020	Peel Hunt	Upgrade	Buy	GBX 1,990 ➝ GBX 2,380	i
3/31/2020	Peel Hunt	Reiterated Rating	Hold		i
3/12/2020	Jefferies Financial Group	Boost Price Target	Buy	GBX 2,300 ➝ GBX 2,390	i
3/10/2020	Citigroup	Upgrade	Buy	GBX 1,980 ➝ GBX 2,150	i
3/5/2020	Peel Hunt	Reiterated Rating	Hold		i
3/2/2020	Barclays	Boost Price Target	Equal weight	GBX 1,900 ➝ GBX 1,950	i
2/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Underweight		i
2/28/2020	Citigroup	Reiterated Rating	Neutral		i
2/24/2020	Peel Hunt	Reiterated Rating	Hold		i
2/20/2020	Barclays	Reiterated Rating	Equal weight		i
2/18/2020	Peel Hunt	Reiterated Rating	Hold		i
2/17/2020	Citigroup	Downgrade	Neutral		i
2/5/2020	Peel Hunt	Reiterated Rating	Hold		i
1/27/2020	Peel Hunt	Reiterated Rating	Hold		i
1/21/2020	Jefferies Financial Group	Lower Price Target	Buy	GBX 2,310 ➝ GBX 2,240	i
1/20/2020	Barclays	Reiterated Rating	Equal Weight	GBX 1,900	i
1/10/2020	Peel Hunt	Reiterated Rating	Hold		i
1/6/2020	JPMorgan Chase & Co.	Boost Price Target	Neutral	GBX 1,800 ➝ GBX 1,850	i
12/6/2019	Barclays	Reiterated Rating	Equal weight		i
12/5/2019	Peel Hunt	Reiterated Rating	Hold		i
12/3/2019	JPMorgan Chase & Co.	Boost Price Target	Neutral	GBX 1,700 ➝ GBX 1,800	i
11/27/2019	Peel Hunt	Reiterated Rating	Hold		i
11/27/2019	HSBC	Reiterated Rating	Reduce		i
11/18/2019	Barclays	Reiterated Rating	Equal weight		i
11/15/2019	Jefferies Financial Group	Reiterated Rating	Buy		i
11/13/2019	Morgan Stanley	Reiterated Rating	Equal weight		i
11/7/2019	Citigroup	Reiterated Rating	Buy		i
11/4/2019	Peel Hunt	Reiterated Rating	Hold		i
9/2/2019	Peel Hunt	Reiterated Rating	Hold		i
8/20/2019	Barclays	Boost Price Target	Equal weight	GBX 1,800 ➝ GBX 1,900	i
8/9/2019	Peel Hunt	Reiterated Rating	Hold	GBX 1,870 ➝ GBX 2,050	i
7/29/2019	Peel Hunt	Reiterated Rating	Hold		i
7/3/2019	Peel Hunt	Reiterated Rating	Hold		i
6/18/2019	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 1,700	i
6/4/2019	Peel Hunt	Reiterated Rating	Hold		i
5/17/2019	Peel Hunt	Reiterated Rating	Hold		i
5/3/2019	Barclays	Reiterated Rating	Equal Weight	GBX 1,800	i
5/2/2019	Peel Hunt	Reiterated Rating	Hold		i
4/10/2019	Barclays	Reiterated Rating	Equal weight		i
4/2/2019	Peel Hunt	Reiterated Rating	Hold		i
3/21/2019	Barclays	Lower Price Target	Equal weight	GBX 1,950 ➝ GBX 1,800	i
3/19/2019	Citigroup	Upgrade	Buy		i
3/19/2019	Jefferies Financial Group	Lower Price Target	Buy	GBX 2,000 ➝ GBX 1,960	i
3/14/2019	HSBC	Boost Price Target	Reduce	GBX 1,225 ➝ GBX 1,350	i
3/14/2019	JPMorgan Chase & Co.	Lower Price Target	Neutral	GBX 1,800 ➝ GBX 1,700	i
3/13/2019	Numis Securities	Reiterated Rating	Hold	GBX 1,730	i
3/12/2019	Peel Hunt	Lower Price Target	Hold	GBX 2,000 ➝ GBX 1,870	i
1/31/2019	Peel Hunt	Reiterated Rating	Hold		i
1/21/2019	Barclays	Reiterated Rating	Equal weight		i
1/15/2019	Barclays	Reiterated Rating	Equal weight		i
1/7/2019	Peel Hunt	Reiterated Rating	Hold		i
1/2/2019	JPMorgan Chase & Co.	Lower Price Target	Neutral	GBX 1,900 ➝ GBX 1,800	i
12/19/2018	Barclays	Reiterated Rating	Equal weight		i
12/7/2018	Barclays	Reiterated Rating	Equal weight		i
12/6/2018	Peel Hunt	Reiterated Rating	Hold		i
11/27/2018	Jefferies Financial Group	Upgrade	Buy	GBX 1,643 ➝ GBX 2,000	i
11/20/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral	GBX 1,050 ➝ GBX 1,900	i
11/12/2018	Peel Hunt	Downgrade	Hold	GBX 1,950 ➝ GBX 2,000	i
11/9/2018	Barclays	Reiterated Rating	Equal Weight	GBX 1,950	i
11/8/2018	Peel Hunt	Reiterated Rating	Add		i
11/6/2018	Barclays	Upgrade	Equal weight	GBX 1,400 ➝ GBX 1,800	i
11/1/2018	Peel Hunt	Reiterated Rating	Add		i
10/30/2018	Citigroup	Reiterated Rating	Buy	GBX 2,250	i
10/23/2018	Peel Hunt	Reiterated Rating	Add		i
10/15/2018	Barclays	Reiterated Rating	Underweight		i
10/9/2018	Barclays	Reiterated Rating	Underweight		i
10/3/2018	Peel Hunt	Reiterated Rating	Add		i
10/3/2018	Citigroup	Boost Price Target	Buy	GBX 2,100 ➝ GBX 2,250	i
9/24/2018	Barclays	Reiterated Rating	Underweight		i
9/17/2018	Barclays	Reiterated Rating	Underweight		i
9/4/2018	Peel Hunt	Reiterated Rating	Add		i
8/24/2018	Barclays	Reiterated Rating	Underweight	GBX 1,400	i
8/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 1,050	i
8/20/2018	Citigroup	Boost Price Target	Buy	GBX 1,675 ➝ GBX 2,100	i
8/16/2018	Barclays	Reiterated Rating	Underweight		i
8/16/2018	Peel Hunt	Upgrade	Add	GBX 1,160 ➝ GBX 1,950	i
8/15/2018	Numis Securities	Reiterated Rating	Hold		i
8/15/2018	Peel Hunt	Reiterated Rating	Hold	GBX 1,160	i
8/10/2018	Barclays	Reiterated Rating	Underweight		i
8/9/2018	Numis Securities	Downgrade	Hold	GBX 1,560	i
8/1/2018	Peel Hunt	Reiterated Rating	Hold		i
7/19/2018	Barclays	Reiterated Rating	Underweight		i
7/10/2018	Barclays	Reiterated Rating	Underweight		i
7/3/2018	Citigroup	Reiterated Rating	Buy	GBX 1,675	i
7/3/2018	Peel Hunt	Reiterated Rating	Hold		i
5/31/2018	Peel Hunt	Reiterated Rating	Hold		i
5/21/2018	Barclays	Reiterated Rating	Underweight		i
5/18/2018	Numis Securities	Downgrade	Add	GBX 1,300 ➝ GBX 1,560	i
5/18/2018	Jefferies Financial Group	Reiterated Rating	Hold	GBX 997	i
5/18/2018	Peel Hunt	Reiterated Rating	Hold		i
5/1/2018	Citigroup	Boost Price Target	Buy	GBX 1,250 ➝ GBX 1,475	i
4/4/2018	Peel Hunt	Reiterated Rating	Hold		i
3/20/2018	Peel Hunt	Lower Price Target	Hold	GBX 1,180 ➝ GBX 1,160	i
3/19/2018	Barclays	Reiterated Rating	Underweight	GBX 800 ➝ GBX 850	i
3/15/2018	Morgan Stanley	Boost Price Target	Equal weight	GBX 1,000 ➝ GBX 1,050	i
3/15/2018	Citigroup	Upgrade	Buy	GBX 1,250	i
3/15/2018	JPMorgan Chase & Co.	Boost Price Target	Neutral	GBX 1,000 ➝ GBX 1,050	i
3/15/2018	Jefferies Financial Group	Upgrade	Hold	GBX 895 ➝ GBX 997	i
3/14/2018	Peel Hunt	Reiterated Rating	Hold	GBX 1,180	i
3/14/2018	Numis Securities	Initiated Coverage	Buy	GBX 1,300	i
3/1/2018	Barclays	Downgrade	Underweight	GBX 1,500 ➝ GBX 800	i
2/15/2018	Peel Hunt	Lower Price Target	Hold	GBX 1,390 ➝ GBX 1,180	i
2/1/2018	Peel Hunt	Reiterated Rating	Hold	GBX 1,390	i
1/17/2018	Jefferies Financial Group	Reiterated Rating	Underperform	GBX 895	i
1/15/2018	JPMorgan Chase & Co.	Reiterated Rating	Neutral		i
1/10/2018	Jefferies Financial Group	Downgrade	Underperform	GBX 1,074 ➝ GBX 895	i
12/20/2017	Numis Securities	Reiterated Rating	Buy	GBX 1,300	i
12/4/2017	Jefferies Financial Group	Boost Price Target	Hold	GBX 1,045 ➝ GBX 1,074	i
12/1/2017	Morgan Stanley	Reiterated Rating	Equal weight	GBX 1,100	i
11/15/2017	Peel Hunt	Reiterated Rating	Hold	GBX 1,390	i
11/10/2017	JPMorgan Chase & Co.	Lower Price Target	Neutral	GBX 1,250 ➝ GBX 1,000	i
11/9/2017	Peel Hunt	Reiterated Rating	Hold	GBX 1,390	i
11/9/2017	Stifel Nicolaus	Lower Price Target	Hold	GBX 1,320 ➝ GBX 1,000	i
11/9/2017	Numis Securities	Upgrade	Buy	GBX 1,300	i
11/9/2017	Jefferies Financial Group	Reiterated Rating	Hold	GBX 1,045	i
10/31/2017	Peel Hunt	Reiterated Rating	Hold	GBX 1,390	i
10/6/2017	JPMorgan Chase & Co.	Lower Price Target	Neutral	GBX 1,500 ➝ GBX 1,250	i
9/29/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		i
8/29/2017	Stifel Nicolaus	Downgrade	Hold	GBX 2,300 ➝ GBX 1,320	i
8/25/2017	Barclays	Lower Price Target	Overweight	GBX 2,200 ➝ GBX 1,500	i
8/24/2017	Citigroup	Reiterated Rating	Neutral	GBX 1,350	i
8/22/2017	The Goldman Sachs Group	Downgrade	Neutral	GBX 2,600 ➝ GBX 1,310	i
8/21/2017	Morgan Stanley	Downgrade	Equal weight	GBX 1,600 ➝ GBX 1,350	i
8/21/2017	Jefferies Financial Group	Lower Price Target	Hold	GBX 1,390 ➝ GBX 1,045	i
8/17/2017	Numis Securities	Reiterated Rating	Add	GBX 1,560	i
8/17/2017	Peel Hunt	Reiterated Rating	Hold	GBX 2,150	i
8/11/2017	Numis Securities	Reiterated Rating	Add	GBX 1,560	i
8/2/2017	Morgan Stanley	Downgrade	Equal Weight	GBX 2,050 ➝ GBX 1,600	i
7/3/2017	Barclays	Reiterated Rating	Overweight	GBX 2,200	i
6/28/2017	Citigroup	Reiterated Rating	Neutral	GBX 1,550	i
6/28/2017	Jefferies Financial Group	Lower Price Target	Underweight	GBX 1,450 ➝ GBX 1,390	i
6/27/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 1,500	i
6/2/2017	Jefferies Financial Group	Reiterated Rating	Underperform	GBX 1,450	i
5/22/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 1,800 ➝ GBX 1,500	i
5/19/2017	Numis Securities	Reiterated Rating	Add	GBX 2,000	i
5/17/2017	Jefferies Financial Group	Downgrade	Underperform	GBX 2,162 ➝ GBX 1,450	i
5/12/2017	JPMorgan Chase & Co.	Lower Price Target	Neutral	GBX 2,400 ➝ GBX 1,800	i
5/11/2017	Numis Securities	Reiterated Rating	Buy	GBX 2,350	i
4/10/2017	Numis Securities	Upgrade	Buy	GBX 2,350	i
4/6/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 2,400	i
4/4/2017	Stifel Nicolaus	Reiterated Rating	Buy	GBX 2,550	i
3/30/2017	Numis Securities	Reiterated Rating	Add	GBX 2,350	i
3/30/2017	Peel Hunt	Reiterated Rating	Buy		i
3/28/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 2,400	i
3/22/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	GBX 2,400	i
3/16/2017	JPMorgan Chase & Co.	Downgrade	Neutral	GBX 2,100 ➝ GBX 2,400	i
3/15/2017	Peel Hunt	Reiterated Rating	Buy	GBX 2,340	i
3/13/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight		i
3/10/2017	Numis Securities	Downgrade	Add	GBX 2,350	i
2/24/2017	Peel Hunt	Reiterated Rating	Buy	GBX 2,340	i
1/25/2017	Peel Hunt	Initiated Coverage	Buy	GBX 2,340	i
1/17/2017	Jefferies Financial Group	Boost Price Target	Buy	GBX 2,065 ➝ GBX 2,162	i
1/17/2017	JPMorgan Chase & Co.	Reiterated Rating	Overweight	GBX 2,100	i
1/4/2017	JPMorgan Chase & Co.	Lower Price Target	Overweight	GBX 2,450 ➝ GBX 2,100	i
12/15/2016	Jefferies Financial Group	Boost Price Target	Buy	GBX 2,000 ➝ GBX 2,065	i
12/6/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight	GBX 2,450	i
11/30/2016	AlphaValue	Reiterated Rating	Buy	GBX 2,431	i
11/17/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		i
11/16/2016	Citigroup	Reiterated Rating	Neutral		i
11/15/2016	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	GBX 2,500 ➝ GBX 2,200	i
11/11/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		i
11/11/2016	Jefferies Financial Group	Lower Price Target	Buy	GBX 2,500 ➝ GBX 2,000	i
11/10/2016	Numis Securities	Reiterated Rating	Buy	GBX 2,350	i
11/4/2016	Numis Securities	Upgrade	Buy	GBX 2,350	i
9/23/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight		i
9/14/2016	JPMorgan Chase & Co.	Lower Price Target	Overweight	GBX 2,550 ➝ GBX 2,450	i
9/12/2016	Jefferies Financial Group	Lower Price Target	Buy	GBX 2,990 ➝ GBX 2,500	i
9/9/2016	Barclays	Reiterated Rating	Overweight	GBX 2,900	i
8/24/2016	Numis Securities	Reiterated Rating	Hold	GBX 2,660	i
8/23/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight	GBX 2,550	i
8/16/2016	JPMorgan Chase & Co.	Reiterated Rating	Overweight	GBX 2,550	i
8/12/2016	Morgan Stanley	Lower Price Target	Equal weight	GBX 2,700 ➝ GBX 2,500	i
8/4/2016	Citigroup	Downgrade	Neutral	GBX 2,600	i
8/4/2016	JPMorgan Chase & Co.	Lower Price Target	Overweight	GBX 2,800 ➝ GBX 2,550	i
8/4/2016	Numis Securities	Downgrade	Hold	GBX 2,660	i
8/4/2016	Jefferies Financial Group	Reiterated Rating	Buy	GBX 2,990	i
8/4/2016	Barclays	Reiterated Rating	Overweight	GBX 2,800	i
7/26/2016	Jefferies Financial Group	Boost Price Target	Buy	GBX 2,800 ➝ GBX 2,990	i
7/22/2016	Numis Securities	Initiated Coverage	Add	GBX 2,830	i
7/21/2016	Morgan Stanley	Initiated Coverage	Equal weight	GBX 2,700	i
7/5/2016	Jefferies Financial Group	Boost Price Target	Buy	GBX 2,380 ➝ GBX 2,800	i
6/24/2016	Stifel Nicolaus	Reiterated Rating	Buy		i

(Data available from 6/14/2016 forward)

Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment develops, manufactures, and sells generic injectable products primarily for use in hospitals. The Generics segment develops, manufactures, and sells oral and other non-injectable generic products for the retail market. The Branded segment develops, manufactures, markets, and sells branded generics and in-licensed products to retail and hospital markets. The company offers its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, anesthetic, sedative, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Today's Range

Now: GBX 2,468

2,451

2,469

50 Day Range

MA: GBX 2,400.68

2,301

2,496

52 Week Range

Now: GBX 2,468

2,086.49

2,768

Volume

12,275 shs

Average Volume

393,379 shs

Market Capitalization

£5.71 billion

P/E Ratio

19.31

Dividend Yield

1.50%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Morgan Stanley, and Peel Hunt.
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 2,717.50, suggesting a possible upside of 10.1%. Peel Hunt has the highest price target set, predicting HIK will reach GBX 2,860 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of GBX 2,600 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HIK will outperform the market and that investors should add to their positions of Hikma Pharmaceuticals.
View the latest ratings for HIK.

What other companies compete with Hikma Pharmaceuticals?

Other companies that are similar to Hikma Pharmaceuticals include MERCK Kommanditgesellschaft auf Aktien, Bausch Health Companies, Canopy Growth, Evotec, Aphria, Leaf Mobile, Aurora Cannabis, HEXO, OrganiGram, Knight Therapeutics, HLS Therapeutics, Benchmark, Amryt Pharma, The Supreme Cannabis and ICC Labs.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com.